Logo image of OMGA

OMEGA THERAPEUTICS INC (OMGA) Stock Fundamental Analysis

USA - NASDAQ:OMGA - US68217N1054 - Common Stock

0.1426 USD
-0.02 (-10.82%)
Last: 2/24/2025, 8:00:02 PM
0.11 USD
-0.03 (-22.86%)
After Hours: 2/24/2025, 8:00:02 PM
Fundamental Rating

2

Overall OMGA gets a fundamental rating of 2 out of 10. We evaluated OMGA against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of OMGA have multiple concerns. While showing a medium growth rate, OMGA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year OMGA has reported negative net income.
OMGA had a negative operating cash flow in the past year.
In the past 5 years OMGA always reported negative net income.
In the past 5 years OMGA always reported negative operating cash flow.
OMGA Yearly Net Income VS EBIT VS OCF VS FCFOMGA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -47.86%, OMGA is in line with its industry, outperforming 48.17% of the companies in the same industry.
With a Return On Equity value of -633.21%, OMGA is not doing good in the industry: 80.98% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -47.86%
ROE -633.21%
ROIC N/A
ROA(3y)-49.09%
ROA(5y)-109.27%
ROE(3y)-99.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OMGA Yearly ROA, ROE, ROICOMGA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

OMGA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OMGA Yearly Profit, Operating, Gross MarginsOMGA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -1K -2K -3K -4K

1

2. Health

2.1 Basic Checks

OMGA does not have a ROIC to compare to the WACC, probably because it is not profitable.
OMGA has more shares outstanding than it did 1 year ago.
The debt/assets ratio for OMGA has been reduced compared to a year ago.
OMGA Yearly Shares OutstandingOMGA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
OMGA Yearly Total Debt VS Total AssetsOMGA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.95, we must say that OMGA is in the distress zone and has some risk of bankruptcy.
OMGA has a Altman-Z score of -4.95. This is in the lower half of the industry: OMGA underperforms 60.73% of its industry peers.
OMGA has a Debt/Equity ratio of 1.00. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.00, OMGA is doing worse than 78.53% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Altman-Z -4.95
ROIC/WACCN/A
WACC9.59%
OMGA Yearly LT Debt VS Equity VS FCFOMGA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 1.61 indicates that OMGA should not have too much problems paying its short term obligations.
With a Current ratio value of 1.61, OMGA is not doing good in the industry: 80.80% of the companies in the same industry are doing better.
A Quick Ratio of 1.61 indicates that OMGA should not have too much problems paying its short term obligations.
The Quick ratio of OMGA (1.61) is worse than 79.76% of its industry peers.
Industry RankSector Rank
Current Ratio 1.61
Quick Ratio 1.61
OMGA Yearly Current Assets VS Current LiabilitesOMGA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

5

3. Growth

3.1 Past

OMGA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.06%, which is quite impressive.
OMGA shows a strong growth in Revenue. In the last year, the Revenue has grown by 184.04%.
EPS 1Y (TTM)36.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)184.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%214.32%

3.2 Future

OMGA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.60% yearly.
Based on estimates for the next years, OMGA will show a very strong growth in Revenue. The Revenue will grow by 150.92% on average per year.
EPS Next Y34.35%
EPS Next 2Y24.8%
EPS Next 3Y20.55%
EPS Next 5Y23.6%
Revenue Next Year233.18%
Revenue Next 2Y29.68%
Revenue Next 3Y37.19%
Revenue Next 5Y150.92%

3.3 Evolution

OMGA Yearly Revenue VS EstimatesOMGA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
OMGA Yearly EPS VS EstimatesOMGA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 6

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OMGA. In the last year negative earnings were reported.
Also next year OMGA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OMGA Price Earnings VS Forward Price EarningsOMGA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OMGA Per share dataOMGA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as OMGA's earnings are expected to grow with 20.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.8%
EPS Next 3Y20.55%

0

5. Dividend

5.1 Amount

OMGA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

OMEGA THERAPEUTICS INC

NASDAQ:OMGA (2/24/2025, 8:00:02 PM)

After market: 0.11 -0.03 (-22.86%)

0.1426

-0.02 (-10.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)N/A N/A
Inst Owners81.36%
Inst Owner Change0%
Ins Owners1.4%
Ins Owner Change0%
Market Cap7.90M
Revenue(TTM)8.10M
Net Income(TTM)-73092000
Analysts82.86
Price Target13.26 (9198.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.6%
Min EPS beat(2)-6.31%
Max EPS beat(2)19.51%
EPS beat(4)2
Avg EPS beat(4)6.61%
Min EPS beat(4)-6.31%
Max EPS beat(4)19.51%
EPS beat(8)5
Avg EPS beat(8)8.26%
EPS beat(12)8
Avg EPS beat(12)10.33%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)113.47%
Min Revenue beat(2)106.48%
Max Revenue beat(2)120.46%
Revenue beat(4)4
Avg Revenue beat(4)84.74%
Min Revenue beat(4)41.91%
Max Revenue beat(4)120.46%
Revenue beat(8)8
Avg Revenue beat(8)95.37%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)40.54%
PT rev (3m)40.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.75%
EPS NY rev (1m)0%
EPS NY rev (3m)2.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.98
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0.15
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -47.86%
ROE -633.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.09%
ROA(5y)-109.27%
ROE(3y)-99.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.3%
Cap/Sales 25.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.61
Quick Ratio 1.61
Altman-Z -4.95
F-Score4
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)125.73%
Cap/Depr(5y)129.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y34.35%
EPS Next 2Y24.8%
EPS Next 3Y20.55%
EPS Next 5Y23.6%
Revenue 1Y (TTM)184.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%214.32%
Revenue Next Year233.18%
Revenue Next 2Y29.68%
Revenue Next 3Y37.19%
Revenue Next 5Y150.92%
EBIT growth 1Y32.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.82%
EBIT Next 3Y6.19%
EBIT Next 5YN/A
FCF growth 1Y37.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.41%
OCF growth 3YN/A
OCF growth 5YN/A

OMEGA THERAPEUTICS INC / OMGA FAQ

What is the ChartMill fundamental rating of OMEGA THERAPEUTICS INC (OMGA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to OMGA.


Can you provide the valuation status for OMEGA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to OMEGA THERAPEUTICS INC (OMGA). This can be considered as Overvalued.


What is the profitability of OMGA stock?

OMEGA THERAPEUTICS INC (OMGA) has a profitability rating of 0 / 10.